WO2024250024A3 - Vaccin pour chats pour bloquer la libération et la transmission de toxoplasma oocyst - Google Patents

Vaccin pour chats pour bloquer la libération et la transmission de toxoplasma oocyst Download PDF

Info

Publication number
WO2024250024A3
WO2024250024A3 PCT/US2024/032292 US2024032292W WO2024250024A3 WO 2024250024 A3 WO2024250024 A3 WO 2024250024A3 US 2024032292 W US2024032292 W US 2024032292W WO 2024250024 A3 WO2024250024 A3 WO 2024250024A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
toxoplasma
cats
transmission
block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/032292
Other languages
English (en)
Other versions
WO2024250024A2 (fr
Inventor
Michael E. GRIGG
Viviana PSZENNY
Aline SARDINHA DA SILVA
Jitender P. Dubey
Julius LUKES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biologicke Centrum Av Cr V V I
US Department of Agriculture USDA
US Department of Health and Human Services
Original Assignee
Biologicke Centrum Av Cr V V I
US Department of Agriculture USDA
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biologicke Centrum Av Cr V V I, US Department of Agriculture USDA, US Department of Health and Human Services filed Critical Biologicke Centrum Av Cr V V I
Priority to EP24737579.3A priority Critical patent/EP4720275A2/fr
Publication of WO2024250024A2 publication Critical patent/WO2024250024A2/fr
Publication of WO2024250024A3 publication Critical patent/WO2024250024A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un parasite recombinant, qui est un membre du phylum Apicomplexa ou Euglenozoa, et qui comprend un génome dépourvu d'un gène natif codant pour une protéine IFT88, SRS15A, SRS15B, et/ou SRS15C, SRS26B de Toxoplasma gondii, un homologue natif ou un orthologue de celle-ci, ou une combinaison d'au moins deux de celles-ci. L'invention concerne également un procédé de production du parasite recombiné, qui consiste à inactiver un ou plusieurs de ces gènes dans le génome du parasite. L'invention concerne des réactifs pour atteindre cet objectif, ainsi que des compositions de vaccin comprenant les parasites recombinés de l'invention et des compositions de vaccin comprenant une protéine IFT88, SRS15A, SRS15B et/ou SRS15C, SRS26B de Toxoplasma gondii, ou un homologue ou un orthologue de celle-ci, ou une combinaison d'au moins deux de celles-ci. L'invention concerne également des méthodes de vaccination d'animaux à l'aide de telles compositions vaccinales.
PCT/US2024/032292 2023-06-02 2024-06-03 Vaccin pour chats pour bloquer la libération et la transmission de toxoplasma oocyst Ceased WO2024250024A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24737579.3A EP4720275A2 (fr) 2023-06-02 2024-06-03 Vaccin pour chats pour bloquer la libération et la transmission de toxoplasma oocyst

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470773P 2023-06-02 2023-06-02
US63/470,773 2023-06-02

Publications (2)

Publication Number Publication Date
WO2024250024A2 WO2024250024A2 (fr) 2024-12-05
WO2024250024A3 true WO2024250024A3 (fr) 2025-02-13

Family

ID=91758778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032292 Ceased WO2024250024A2 (fr) 2023-06-02 2024-06-03 Vaccin pour chats pour bloquer la libération et la transmission de toxoplasma oocyst

Country Status (2)

Country Link
EP (1) EP4720275A2 (fr)
WO (1) WO2024250024A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120290323A (zh) * 2025-06-13 2025-07-11 江西农业大学 一种Tgsrs51基因缺失的弓形虫减毒虫株及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687471A1 (fr) * 1994-06-17 1995-12-20 Bayer Corporation Production d'un vaccin efficace à partir de bradyzoites de toxoplasma gondii dans une culture tissulaire
US20220235101A1 (en) * 2019-05-31 2022-07-28 Whitehead Institute For Biomedical Research Compositions and Methods for Regulation of Chronic Toxoplasma Infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687471A1 (fr) * 1994-06-17 1995-12-20 Bayer Corporation Production d'un vaccin efficace à partir de bradyzoites de toxoplasma gondii dans une culture tissulaire
US20220235101A1 (en) * 2019-05-31 2022-07-28 Whitehead Institute For Biomedical Research Compositions and Methods for Regulation of Chronic Toxoplasma Infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUXTON D ET AL: "Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant", VETERINARY RECORD, BRITISH VETERINARY ASSOCIATION, LONDON, GB, vol. 129, no. 5, 3 August 1991 (1991-08-03), pages 89 - 93, XP009173140, ISSN: 0042-4900, DOI: 10.1136/VR.129.5.89 *
RALSTON K S ET AL: "The flagellum of Trypanosoma brucei: New tricks from an old dog", INTERNATIONAL JOURNAL OF PARASITOLOGY, PERGAMON PRESS, GB, vol. 38, no. 8-9, 1 July 2008 (2008-07-01), pages 869 - 884, XP026282526, ISSN: 0020-7519, [retrieved on 20080328], DOI: 10.1016/J.IJPARA.2008.03.003 *
RAMAKRISHNAN CHANDRA ET AL: "An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats", SCIENTIFIC REPORTS, vol. 9, no. 1, 6 February 2019 (2019-02-06), US, pages 1474, XP093211804, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-018-37671-8> DOI: 10.1038/s41598-018-37671-8 *

Also Published As

Publication number Publication date
EP4720275A2 (fr) 2026-04-08
WO2024250024A2 (fr) 2024-12-05

Similar Documents

Publication Publication Date Title
Burrell et al. Life cycle stages, specific organelles and invasion mechanisms of Eimeria species
Marshall et al. Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum
Zhang et al. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani
Boothroyd et al. The surface of Toxoplasma: more and less
Yuda et al. von Willebrand Factor A domain-related protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites
Bishop et al. Theileria: intracellular protozoan parasites of wild and domestic ruminants transmitted by ixodid ticks
Kaslow Transmission-blocking immunity against malaria and other vector-borne diseases
Howe et al. Comparison of the major antigens of Neospora caninum and Toxoplasma gondii
Reid Large, rapidly evolving gene families are at the forefront of host–parasite interactions in Apicomplexa
RU2585226C2 (ru) Вакцинная композиция для борьбы с заражениями эктопаразитами
WO2024250024A3 (fr) Vaccin pour chats pour bloquer la libération et la transmission de toxoplasma oocyst
Wallach The importance of transmission-blocking immunity in the control of infections by apicomplexan parasites
Jongwutiwes et al. Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) ofPlasmodium falciparum from field isolates
Black et al. The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite
Favuzza et al. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA
ES2339227T3 (es) Acidos nucleicos que codifican antigenos recombinantes de 56 y 82 kda de gametocitos de eimeria maxima y sus usos.
Frénal et al. The actomyosin systems in Apicomplexa
Nishisaka et al. Characterisation of the gene encoding a protective antigen from Babesia microti identified it as η subunit of chaperonin containing T-complex protein 1
Barreda et al. Identification of conserved peptides containing B‐cell epitopes of Babesia bovis AMA‐1 and their potential as diagnostics candidates
Mongui et al. Cloning, expression, and characterisation of a Plasmodium vivax MSP7 family merozoite surface protein
Angel et al. The Plasmodium vivax Pv41 surface protein: identification and characterization
Ellis et al. Development of a genetically engineered vaccine against poultry coccidiosis
Mongui et al. Identifying and characterising the Plasmodium falciparum RhopH3 Plasmodium vivax homologue
Rafati et al. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice
DE60235044D1 (de) REKOMBINANTES, 250 kDa GROSSES ANTIGEN AUS SPOROZOITEN/MEROZOITEN VON EIMERIA MAXIMA CODIERENDE NUKLEINSÄUREN UND IHRE VERWENDUNGEN

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24737579

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024737579

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024737579

Country of ref document: EP

Effective date: 20260102

ENP Entry into the national phase

Ref document number: 2024737579

Country of ref document: EP

Effective date: 20260102

ENP Entry into the national phase

Ref document number: 2024737579

Country of ref document: EP

Effective date: 20260102

ENP Entry into the national phase

Ref document number: 2024737579

Country of ref document: EP

Effective date: 20260102

WWP Wipo information: published in national office

Ref document number: 2024737579

Country of ref document: EP